Z978X

**Z978X** is a sponsor-designated investigational combination-drug program from Zyvran Pharmaceuticals for **treatment-resistant depression**. Publicly available pipeline information identifies it as a combination product, but does not disclose its active ingredients, molecular targets, dosage form, route of administration, or specific mechanism of action. A Zyvran patent application for treatment-resistant depression describes candidate compositions comprising an SNRI such as venlafaxine, a tetracyclic antidepressant such as mirtazapine, and a mood stabilizer such as lithium; however, the patent does not explicitly identify that composition as Z978X.